DK2953971T3 - Il-11r-bindende proteiner og anvendelser deraf - Google Patents

Il-11r-bindende proteiner og anvendelser deraf Download PDF

Info

Publication number: DK2953971T3
Authority: DK; Denmark
Prior art keywords: binding proteins; proteins; binding
Prior art date: 2013-02-07

Application number

DK14749445.4T

Other languages

English (en)

Other versions

DK2953971T5 (da

Inventor

Kirsten Mae Edwards

Matthew Philip Hardy

Veronika Rayzman

Michael Wilson

Original Assignee

Csl Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-07

Filing date

2014-02-06

Publication date

2023-05-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51259368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2953971(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-02-07 Priority claimed from AU2013900389A external-priority patent/AU2013900389A0/en

2014-02-06 Application filed by Csl Ltd filed Critical Csl Ltd

2023-05-01 Publication of DK2953971T3 publication Critical patent/DK2953971T3/da

2024-10-14 Application granted granted Critical

2024-10-14 Publication of DK2953971T5 publication Critical patent/DK2953971T5/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Biotechnology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Tropical Medicine & Parasitology (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)

DK14749445.4T 2013-02-07 2014-02-06 Il-11r-bindende proteiner og anvendelser deraf DK2953971T5 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AU2013900389A AU2013900389A0 (en)		2013-02-07	Il-11r binding proteins and uses thereof
US201361764756P	2013-02-14	2013-02-14
PCT/AU2014/000083 WO2014121325A1 (en)	2013-02-07	2014-02-06	Il-11r binding proteins and uses thereof

Publications (2)

Publication Number	Publication Date
DK2953971T3 true DK2953971T3 (da)	2023-05-01
DK2953971T5 DK2953971T5 (da)	2024-10-14

Family

ID=51259368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14749445.4T DK2953971T5 (da)	2013-02-07	2014-02-06	Il-11r-bindende proteiner og anvendelser deraf

Country Status (13)

Country	Link
US (2)	US9340618B2 (da)
EP (2)	EP4219552A3 (da)
JP (3)	JP6545105B2 (da)
KR (1)	KR102489953B1 (da)
CN (3)	CN117843785A (da)
AU (1)	AU2014214530B2 (da)
DK (1)	DK2953971T5 (da)
ES (1)	ES2942636T3 (da)
FI (1)	FI2953971T3 (da)
PL (1)	PL2953971T3 (da)
PT (1)	PT2953971T (da)
SG (1)	SG11201505762XA (da)
WO (1)	WO2014121325A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017049349A1 (en) *	2015-09-25	2017-03-30	Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research	A method of treatment and prophylaxis
GB201522186D0 (en)	2015-12-16	2016-01-27	Singapore Health Services Pte Ltd And Nat University Of Singapore The	Treatment of fibrosis
ES2874974T3 (es) *	2016-05-11	2021-11-05	Cytiva Bioprocess R & D Ab	Matriz de separación
GB201621439D0 (en) *	2016-12-16	2017-02-01	Singapore Health Services Pte Ltd And Nat Univ Of Singapore	IL-11Ra Antibodies
GB201621431D0 (en)	2016-12-16	2017-02-01	Singapore Health Services Pte Ltd And Nat Univ Of Singapore The	Decoy cytokine receptor
CA3045871A1 (en)	2016-12-16	2018-06-21	Singapore Health Services Pte Ltd	Il-11 antibodies
GB201716733D0 (en)	2017-10-12	2017-11-29	Nat Univ Singapore	Treatment of SMC mediated disease
GB201809700D0 (en) *	2018-06-13	2018-08-01	Singapore Health Serv Pte Ltd	IL-11 antibodies
AU2020211695A1 (en)	2019-01-21	2021-09-02	National University Of Singapore	Treatment of hepatotoxicity
GB201902419D0 (en)	2019-02-22	2019-04-10	Singapore Health Serv Pte Ltd	Treatment of kidney injury
CN114364693A (zh)	2019-05-03	2022-04-15	新加坡保健服务私人有限公司	代谢性疾病的治疗和预防
GB201906291D0 (en)	2019-05-03	2019-06-19	Singapore Health Serv Pte Ltd	Treatment and prevention of metabolic diseases
GB202009292D0 (en)	2020-06-18	2020-08-05	Singapore Health Serv Pte Ltd	Treatment and prevention of disease caused by type IV collagen dysfunction
EP3939999A1 (en) *	2020-07-14	2022-01-19	Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
GB202017244D0 (en)	2020-10-30	2020-12-16	Nat Univ Singapore	Methods to extend health-span and treat age-related diseases
CA3211686A1 (en)	2021-02-26	2022-09-01	Bayer Aktiengesellschaft	Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
JP2024526944A (ja)	2021-07-26	2024-07-19	ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー	アルコール性肝疾患の処置および予防
WO2023034809A1 (en)	2021-08-30	2023-03-09	Lassen Therapeutics 1, Inc.	Anti-il-11rα antibodies
CN113735975B (zh) *	2021-09-07	2022-08-12	广东东阳光药业有限公司	一种抗il-11r抗体及其应用
EP4448096A1 (en)	2021-12-16	2024-10-23	Singapore Health Services Pte. Ltd.	Treatment and prevention of glomerular disease
CN120787238A (zh) *	2023-01-06	2025-10-14	拉森医疗公司	用于治疗甲状腺眼病的抗IL-11Rα抗体
TW202506733A (zh)	2023-06-12	2025-02-16	美商安進公司	淋巴毒素β受體促效劑結合蛋白

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en)	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4593089A (en)	1980-07-30	1986-06-03	Abbott Laboratories	Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en)	1985-07-22	1988-06-14	Abbott Laboratories	Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
ES2052027T5 (es)	1988-11-11	2005-04-16	Medical Research Council	Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
PT1696031E (pt)	1991-12-02	2010-06-25	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DE4211351A1 (de)	1992-04-04	1993-10-07	Behringwerke Ag	Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
PT1621554E (pt)	1992-08-21	2009-07-13	Univ Bruxelles	Imunoglobtainas desprovidas de cadeias leves
EP0672068A4 (en)	1992-09-25	1997-02-26	Commw Scient Ind Res Org	TARGET MOLECULES BINDING POLYPEPTIDES.
ATE342970T1 (de) *	1994-12-22	2006-11-15	Genetics Inst Llc	Verwendung eines menschlichen interleukin-11 rezeptors
US6274547B1 (en) *	1996-06-14	2001-08-14	Genetics Institute, Inc.	Methods comprising the use of human interleukin-11 receptor proteins
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
AUPO591797A0 (en)	1997-03-27	1997-04-24	Commonwealth Scientific And Industrial Research Organisation	High avidity polyvalent and polyspecific reagents
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
ATE219517T1 (de)	1995-08-18	2002-07-15	Morphosys Ag	Protein-/(poly)peptidbibliotheken
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6541213B1 (en)	1996-03-29	2003-04-01	University Of Washington	Microscale diffusion immunoassay
JP2000515002A (ja)	1996-06-27	2000-11-14	フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー	標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
CA2244326C (en)	1997-08-11	2006-03-28	Shinichi Eda	Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
DE69840412D1 (de)	1997-10-31	2009-02-12	Genentech Inc	Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
BRPI9910332B8 (pt)	1998-05-06	2021-05-25	Genentech Inc	método para purificação de um polipeptídio a partir de uma composição
US6562622B1 (en)	1998-05-08	2003-05-13	Diatech Pty, Ltd	Continuous in vitro evolution
CA2237915A1 (en) *	1998-05-19	1999-11-19	Stephen Shaughnessy	Osteoporosis treatment
EP1051432B1 (en)	1998-12-08	2007-01-24	Biovation Limited	Method for reducing immunogenicity of proteins
WO2000042430A1 (en)	1999-01-15	2000-07-20	Medtox Scientific, Inc.	Lateral flow test strip
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
JP4336498B2 (ja)	2000-12-12	2009-09-30	メディミューン，エルエルシー	延長した半減期を有する分子ならびにその組成物および用途
US8178098B2 (en)	2001-04-03	2012-05-15	National Jewish Health	Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
AUPR544401A0 (en)	2001-06-04	2001-06-28	Bischof, Robert Juergen	Animal model for allergy
MXPA05000511A (es)	2001-07-12	2005-09-30	Jefferson Foote	Anticuepros super humanizados.
US7205159B2 (en)	2001-08-20	2007-04-17	Proteome Systems Intellectual Property Pty Ltd.	Diagnostic testing process and apparatus
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
WO2004046729A2 (en)	2002-11-21	2004-06-03	The University Of Leicester	Bodily fluid markers of tissue hypoxia
US20050014716A1 (en)	2003-05-21	2005-01-20	Wang Jin Wei	Pancreatic cancer treatment
AU2004245038A1 (en)	2003-06-02	2004-12-16	Alexion Pharmaceuticals, Inc.	De-immunized anti-CD3 antibody
CA2533149A1 (en) *	2003-07-29	2005-02-17	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Il-11 muteins
PT1692182E (pt)	2003-11-05	2010-05-13	Roche Glycart Ag	Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
DK2330121T3 (da)	2004-06-02	2014-12-15	Adalta Pty Ltd	Bindingsdele baseret på haj-IgNar-domæner
CA2580981C (en)	2004-09-22	2013-10-22	Kirin Beer Kabushiki Kaisha	Stabilized human igg4 antibodies
US20070135620A1 (en)	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
US20060263367A1 (en)	2005-05-23	2006-11-23	Fey Georg H	Bispecific antibody devoid of Fc region and method of treatment using same
JP2009504685A (ja)	2005-08-15	2009-02-05	アラーナ・テラピューティクス・リミテッド	新世界霊長類フレームワーク領域を用いる設計された抗体
CN101321538A (zh) *	2005-12-06	2008-12-10	惠氏公司	白细胞介素-11组合物和使用方法
EP1985305A1 (en)	2007-04-24	2008-10-29	Vivalis	Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en)	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
WO2009052588A1 (en)	2007-10-26	2009-04-30	Csl Limited	Cytokine muteins
US8182814B2 (en) *	2007-10-26	2012-05-22	Csl Limited	Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) *	2008-10-14	2013-08-27	Csl Limited	Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
AR074369A1 (es)	2008-11-20	2011-01-12	Genentech Inc	Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
ES2733067T3 (es)	2008-12-19	2019-11-27	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
BRPI1006998A2 (pt)	2009-01-23	2015-08-25	Biogen Idec Inc	Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
JP7536493B2 (ja) *	2020-04-08	2024-08-20	キヤノン株式会社	光学素子、光学機器、撮像装置

2014
- 2014-02-06 KR KR1020157024292A patent/KR102489953B1/ko active Active
- 2014-02-06 ES ES14749445T patent/ES2942636T3/es active Active
- 2014-02-06 FI FIEP14749445.4T patent/FI2953971T3/fi active
- 2014-02-06 US US14/174,009 patent/US9340618B2/en active Active
- 2014-02-06 EP EP23158872.4A patent/EP4219552A3/en active Pending
- 2014-02-06 EP EP14749445.4A patent/EP2953971B1/en active Active
- 2014-02-06 WO PCT/AU2014/000083 patent/WO2014121325A1/en not_active Ceased
- 2014-02-06 CN CN202311698495.5A patent/CN117843785A/zh active Pending
- 2014-02-06 AU AU2014214530A patent/AU2014214530B2/en active Active
- 2014-02-06 PT PT147494454T patent/PT2953971T/pt unknown
- 2014-02-06 PL PL14749445.4T patent/PL2953971T3/pl unknown
- 2014-02-06 DK DK14749445.4T patent/DK2953971T5/da active
- 2014-02-06 SG SG11201505762XA patent/SG11201505762XA/en unknown
- 2014-02-06 CN CN201910868161.5A patent/CN110551217B/zh active Active
- 2014-02-06 JP JP2015556340A patent/JP6545105B2/ja active Active
- 2014-02-06 CN CN201480008007.6A patent/CN104995211B/zh active Active
2015
- 2015-10-19 US US14/886,418 patent/US9796782B2/en active Active
2021
- 2021-10-07 JP JP2021165360A patent/JP7556838B2/ja active Active
2024
- 2024-09-12 JP JP2024158049A patent/JP2025000680A/ja active Pending

Also Published As

Publication number	Publication date
EP2953971A1 (en)	2015-12-16
JP2025000680A (ja)	2025-01-07
EP2953971A4 (en)	2016-10-12
FI2953971T3 (fi)	2023-04-27
CN110551217A (zh)	2019-12-10
US9796782B2 (en)	2017-10-24
AU2014214530B2 (en)	2014-10-16
WO2014121325A1 (en)	2014-08-14
CN110551217B (zh)	2023-12-15
KR20150115018A (ko)	2015-10-13
EP2953971B1 (en)	2023-03-01
KR102489953B1 (ko)	2023-01-20
PL2953971T3 (pl)	2023-07-03
PT2953971T (pt)	2023-05-02
ES2942636T3 (es)	2023-06-05
SG11201505762XA (en)	2015-08-28
CN117843785A (zh)	2024-04-09
JP2022028651A (ja)	2022-02-16
JP6545105B2 (ja)	2019-07-17
CA2898618A1 (en)	2014-08-14
AU2014214530A1 (en)	2014-09-11
JP7556838B2 (ja)	2024-09-26
EP4219552A2 (en)	2023-08-02
US20160031999A1 (en)	2016-02-04
CN104995211A (zh)	2015-10-21
JP2016515094A (ja)	2016-05-26
US20140219919A1 (en)	2014-08-07
EP4219552A3 (en)	2023-09-13
US9340618B2 (en)	2016-05-17
HK1217502A1 (en)	2017-01-13
CN104995211B (zh)	2019-09-13
DK2953971T5 (da)	2024-10-14

Publication	Publication Date	Title
IL290972A (en)	2022-05-01	Anti-vista antibodies and fragments
DK2953971T5 (da)	2024-10-14	Il-11r-bindende proteiner og anvendelser deraf
DK2970464T3 (da)	2020-08-03	Anti-lag-3-bindende proteiner
DK2970460T3 (da)	2020-06-02	Anti-IL-33-antistoffer og anvendelser deraf
DK3019533T3 (da)	2020-03-23	Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3027204T3 (da)	2022-04-19	Flerdelte signaleringsproteiner og anvendelser deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
IL246921B (en)	2019-09-26	Binding proteins and methods of use thereof
DK3581207T3 (da)	2023-02-06	Fusionsproteiner omfattende hoxd12 og nemo-bindingsdomæne og anvendelse deraf
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3027209T3 (da)	2020-11-02	Anti-Activin A-antistoffer og anvendelser deraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2812356T3 (da)	2019-07-08	CDIM-bindende proteiner og anvendelser deraf
DK2951203T3 (da)	2019-08-12	Heterodimere proteiner
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
LT3041864T (lt)	2021-10-11	Il-18 surišantis baltymas (il-18p) uždegiminių ligų atvejais
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK3058936T3 (da)	2019-05-13	Peptidsammensætning og anvendelser deraf
DK2968173T3 (da)	2020-12-21	Heterocykliske forbindelser og anvendelser deraf
HUE051357T2 (hu)	2021-03-01	IL-23 kötõ antitestek
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf